Kentucky health officials warn against use of kratom
'It is sold in Kentucky. Usually, it will come in either an herbal powder form or in a pill form,' said Program Director for Voices of Hope Lexington, Jimmy Chadwell.
Kentucky health officials warn against use of kratom
Kentucky judge tells lawmakers child removal process doesn't move quick enough in abuse investigations
1 charged, shelter-in-place ended in Saunders Lane after Boone County shooting investigation
In early June, the Kentucky Department for Public Health and the Kentucky Office of Drug Control Policy put out a health alert advising the public not to consume kratom products and products containing 7-hydroxymitragynine, better known as 7-OH. It is a chemical compound found in kratom.
The health agencies warned that when 7-OH is concentrated or synthetically made, it can increase the risk of overdose, severe health issues, and death.
Chadwell urges those using pure kratom products for their harm-reduction benefits to do so wisely.
Kentuckians spend the 3rd highest share of their income on fast food
Bill could make federal minimum wage $15: Kentucky among states paying less than that
Kentucky sitting near bottom of rankings in environmental protection: Study
'Exercise caution. Moderate the amount you use. Never use it alone. Always have Narcan available. Okay? Because of these kratom and the 7-OH, they work on the opioid receptors. So having Narcan available is really going to save somebody's life,' he told FOX 56.
Kratom is not FDA-approved and is illegal in six states.
But Chadwell said that Voices of Hope, an organization for people recovering from substance abuse disorders, believes the answer is not more laws; it is more conversation.
'We believe that creating more laws surrounding drugs and drug users will not help the community. Instead, we feel that supporting increases in the availability of education and encouraging harm reduction initiatives when using any substance are the best route to go,' he said.
Read more of the latest health and wellness news
Health officials also said there are no guarantees that kratom products contain the ingredients the packages claim, have the correct concentrations, or are free from contaminants or other drugs.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
WebMD
3 hours ago
- WebMD
FDA OKs First-of-Its-Kind Lung Cancer Pill
approval to a first-of-its-kind pill for a type of lung cancer known as non-small-cell lung cancer (NSCLC). The drug, called sunvozertinib and sold as Zegfrovy, is for adults with advanced non-small-cell lung cancer (NSCLC). It works for people whose cancer has a certain genetic change, called an EGFR exon 20 insertion mutation. This drug is used when the cancer has gotten worse during or after chemotherapy. It is taken by mouth once a day, making it easier for patients to stick to their treatment, which can go on for a long time. The FDA also approved a test called the Oncomine Dx Express Test. This test helps find the EGFR exon 20 insertion mutation in people with NSCLC who might get Zegfrovy. The test gives results in just 24 hours, so doctors can find the mutation fast and start treatment sooner. NSCLC is the most common type of lung cancer, accounting for about 80% to 85% of all cases. Among these, EGFR exon 20 insertions are the third most common type of EGFR mutation and play a key role in helping cancer cells grow and spread. These cancers are often hard to treat because the mutations can vary from person to person, making it difficult to find effective treatment options. The FDA's approval was based on a clinical trial involving 85 people with advanced NSCLC and EGFR exon 20 insertion mutations whose cancer had worsened despite chemotherapy. They received oral Zegfrovy once daily until their cancer got worse or side effects became too severe. Results showed about 46% of them responded to the treatment, with benefits lasting for more than 11 months. Zegfrovy works by blocking bad EGFR proteins that help cancer cells grow. It is made to target many kinds of EGFR changes, including exon 20 insertion mutations, but it mostly leaves healthy cells alone. It may also help treat other rare EGFR changes and HER2 exon 20 insertion mutations. Ongoing approval may depend on confirming how well the drug works in further studies, according to a news release from Dizal, the drug's maker. In a statement, Pasi A. Jänne, MD, PhD, of the Dana-Farber Cancer Institute of Harvard Medical School and lead principal investigator of the clinical trial, said results from the study show that Zegfrovy works well for patients of different backgrounds. He noted that it's easy to take because it's just one pill a day, which helps people stick to their treatment – something that's really important as lung cancer care becomes more like managing a long-term illness. People taking Zegfrovy should know that the drug may cause serious side effects, including lung inflammation, stomach and skin problems, eye issues, and harm to an unborn baby.
Axios
4 hours ago
- Axios
Vaccine startup nets $45 million in funding despite wider skepticism
Not too long ago, mRNA vaccines were viewed as one of the country's most significant biotech breakthroughs. Safe, effective, and well-funded. Today, they're viewed with skepticism — if not outright fear — by many Americans, including HHS chief RFK Jr. So it seems like an unlikely time to raise $45 million in venture capital funding for an mRNA vax startup, let alone one working on a universal flu vaccine. But that's just what Silicon Valley-based Centivax did yesterday, led by Steve Jurvetson's Future Ventures. Centivax is the second startup from Jake Glanville, who many may recall as the curly-haired guy featured on Netflix's "Pandemic" documentary series — filmed before COVID but airing right as it exploded. His first was an antibody developer called Distributed Bio, which sold to Charles River Labs in 2021 but let Glanville keep the underlying tech. Centivax initially raised some seed capital from NFX and Global Health Investment Fund, plus non-dilutive funding from The Gates Foundation, U.S. Army and U.S. Navy. It's already begun manufacturing, done a variety of animal tests (including on pigs, which get the flu), and on human immune organoids. Phase 1 clinical trials come next, with expectations that they could go quicker than usual given the ubiquity of influenza in both hemispheres. Glanville acknowledges the fraught political climate, but argues that "it's not as bad as some news articles would lead you to believe." He believes that confusing vaccine messaging during the pandemic is partially to blame for mRNA hesitancy. Plus the spate of myocarditis cases for young men, which Glanville attributes to coronavirus' unique "spike" — something he thinks would normally have been engineered out of a vaccine, but wasn't given the time constraints. "This FDA already has fast-tracked a couple of mRNA vaccines," Glanville says, adding that both President Trump and FDA chief Marty Makary have said they want a universal flu vaccine. "They just put $500 million toward a universal flu shot effort — not ours, but they think mRNA needs more study and we're here to do more study." Centivax believes that its tech eventually could apply to universal coronavirus, malaria, HIV and herpes viruses that may be linked to Alzheimer's disease.
UPI
5 hours ago
- UPI
Hims & Hers to bring generic semaglutide to Canada
epa10538868 A package of prescribtion drug Wegovy by Novo Nordisk sits on a table in Copenhagen, Denmark, 23 March 2023. US celebrities have credited their weight loss to the FDA-approved medications that are prescribed to treat Type 2 diabetes. EPA-EFE/Ida Marie Odgaard DENMARK OUT July 9 (UPI) -- The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as Wegovy, will soon expire. Hims & Hers also said in a press release Wednesday that it acquired the European digital health platform ZAVA, which carries Wegovy. Novo Nordisk declared last month it had stopped allowing Hims & Hers to sell Wegovy in its pharmacy due to allegations of "disseminating deceptive marketing" and mass sales of compounded drugs under the pretense of "personalization." However, with ZAVA, Hims & Hers can better reach across markets, and reports it plans to bring semaglutides in Canada. "Our planned expansion into Canada proves our commitment to bringing modern, effective care to those who need it most," said Hims & Hers GM International David Meinertz. "Making affordable, holistic obesity treatment accessible has the potential to help strengthen the local healthcare system and unlock the potential for millions of Canadians to live healthier, more fulfilling lives." There is currently no generic version of semaglutide approved by the Canadian health agency for sale, but the approval process for companies is underway. As for why Novo would allow its patents to expire, a spokesperson told CNBC that all intellectual property decisions are "carefully considered," and that "periods of exclusivity for pharmaceutical products end as part of their normal life cycle and generic treatments may become available over time." Novo lost its Canadian patent after its lawyers requested a refund for the 2017 patent maintenance fee because the company wanted more time to see if it wanted to pay the required $185. Two years later, Novo had still failed to pay and the Canadian government let the patent lapse in 2020. The 2024 Canadian semaglutide market generated $1.18 billion in revenue, and is expected to surpass $4 billion by 2035, according to market research firm Grand View Research.
